BiomX's Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand
Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems
BiomX Accelerates Defense Technology Buildout with DFSL Acquisition
BiomX Inc. (PHGE) Shareholder/Analyst Call Prepared Remarks Transcript
BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
BiomX Adds Former Mossad Deputy to Advisory Board
BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations
BiomX CEO Issues Letter to Stockholders
BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth
BiomX Issues Statement Regarding Recent Common Stock Trading Activity
All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy
BiomX Announces $3.0 Million Private Placement
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
BiomX Inc. Announces 1-for-19 Reverse Stock Split
BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
BiomX : Introduction
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
BiomX Announces a Mandatory Unit Separation
BiomX Stock Gains From Favorable Study Data Presentation on BX004
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript
BiomX Inc. Announces 1-for-10 Reverse Stock Split
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance